Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APETx2 is a 42-amino-acid disulfide-rich peptide toxin originally isolated from the sea anemone Anthopleura elegantissima. It is a highly potent and selective inhibitor of acid-sensing ion channel 3 (ASIC3), a proton-gated sodium channel implicated in pain perception and acidosis-related tissue injury. APETx2 blocks homomeric ASIC3 channels (IC50 = 63 nM), with reduced affinity for heteromeric ASIC channels containing ASIC3 subunits, while exhibiting negligible activity against ASIC1a, ASIC1b, ASIC2a, and major voltage-gated sodium or potassium channels. Its analgesic properties have been demonstrated in rodent pain models, and recent research also suggests cardioprotective effects in myocardial ischemia-reperfusion injury models, likely by inhibiting ASIC3 and exerting downstream metabolic and signaling effects. Structurally, APETx2 features three disulfide bridges stabilizing a four-stranded β-sheet fold, sharing a structural family with other sea anemone toxins but exhibiting a unique pharmacological profile. The APETx2 peptide is primarily used as a research tool for deciphering ASIC3 biology and as a template for developing novel analgesic or cardioprotective agents[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APETx2.